Japan Panel Approves New Alzheimer’s Drug
An expert panel of Japan’s health ministry Monday approved an Alzheimer’s drug jointly developed by Japanese drugmaker Eisai Co. and U.S. partner Biogen Inc.
Lecanemab, sold as Leqembi in the United States, is the first Alzheimer’s treatment confirmed effective in slowing the progression of symptoms.




